# US 2024/0173413 A1 · Ultrasound Responsive Nanobubble Compositions and Methods of Production and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173413 A1
- Document ID: US20240173413A1
- Status: Published application
- Kind: A1
- Application number: 18/553,307
- Filed: 2022-03-30
- Published: 2024-05-30
- Earliest claimed: 2021-04-01
- Assignees: University of Central Florida Research Foundation, lnc.
- Applicants: University of Central Florida Research Foundation, lnc.
- Inventors: Angela SHAR; Mehdi RAZAVI
- Web page: https://patentgrep.com/patent/US20240173413A1

## CPC

- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61K 49/222: {characterised by a special physical form, e.g. emulsions, liposomes}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61K 9/5192: {Processes}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1875: {Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor}
- A61K 48/0033: {the non-active part being non-polymeric}
- A61P 19/10: for osteoporosis
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions, methods, and kits relating to ultrasound targeted nanobubble compositions are disclosed. The nanobubble compositions comprise a hollow core containing at least one gas; at least one therapeutic agent disposed in the hollow core; a polymer shell encircling the hollow core; and at least one targeting agent incorporated in the polymer shell. Methods of producing and using the nanobubble compositions are also disclosed.

## Claims

### Claim 1

An ultrasound responsive targeted nanobubble composition, comprising:
a hollow core containing at least one gas;
a polymer shell encircling the hollow core;
at least one therapeutic agent disposed in the hollow core and/or encapsulated within the polymer shell; and
at least one targeting agent incorporated in the polymer shell and/or attached to a surface of the polymer shell, wherein the at least one targeting agent targets the nanobubble composition to at least a portion of a musculoskeletal system of a patient.

### Claim 2 (depends on 1)

The nanobubble composition of claim 1, wherein the at least one therapeutic agent comprises an siRNA.

### Claim 3 (depends on 2)

The nanobubble composition of claim 2, wherein the siRNA is selected from the group consisting of a Cathepsin K (CTSK) siRNA, histone deacetylase 5 (HDAC5) siRNA, osteoprotegerin (OPG) siRNA, LDL receptor-related protein 5 (LRP5) siRNA, sclerostin siRNA, and combinations thereof.

### Claim 4 (depends on 3)

The nanobubble composition of claim 3, wherein the siRNA is a CTSK siRNA.

### Claim 5 (depends on 1)

The nanobubble composition of claim 1, wherein the at least one therapeutic agent comprises at least one gene sequence selected from the group consisting of vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMP), hepatocyte growth factor (HGF), and combinations thereof.

### Claim 6 (depends on 1)

The nanobubble composition of claim 1, wherein the at least one therapeutic agent comprises CTSK siRNA and at least one gene sequence selected from BMP and VEGF.

### Claim 7 (depends on 1)

The nanobubble composition of claim 1, wherein the at least one gas is perfluorocarbon gas.

### Claim 8 (depends on 1)

The nanobubble composition of claim 1, wherein the polymer shell comprises albumin.

### Claim 9 (depends on 1)

The nanobubble composition of claim 1, wherein the at least one targeting agent comprises alendronate.

### Claim 10 (depends on 1)

The nanobubble composition of claim 1, wherein the nanobubble composition has a diameter in a range of from about 20 nm to about 200 nm in diameter.

### Claim 11 (depends on 1)

The nanobubble composition of claim 1, further comprising at least one imaging agent disposed in the hollow core and/or incorporated in the polymer shell.

### Claim 12

A method of preparing an ultrasound responsive targeted nanobubble composition, the method comprising the steps of:
(1) mixing at least one therapeutic agent with at least one gas and at least one polymer to form a first mixture;
(2) sonicating the first mixture to form nanobubbles that comprise a polymer shell formed about a hollow core containing the at least one therapeutic agent and the at least one gas;
(3) isolating the nanobubbles; and
(4) contacting the nanobubbles with at least one targeting agent to form a second mixture and incubating the second mixture under conditions that allow the at least one targeting agent to be incorporated in the polymer shell and/or attached to a surface of the polymer shell to form the nanobubble composition.

### Claim 13 (depends on 12)

The method of claim 12, wherein the at least one targeting agent targets the nanobubble composition to at least a portion of a musculoskeletal system of a patient.

### Claim 14 (depends on 12)

The method of claim 12, wherein the at least one targeting agent comprises an siRNA.

### Claim 15 (depends on 14)

The method of claim 14, wherein the siRNA is selected from the group consisting of a Cathepsin K (CTSK) siRNA, histone deacetylase 5 (HDAC5) siRNA, osteoprotegerin (OPG) siRNA, LDL receptor-related protein 5 (LRP5) siRNA, sclerostin siRNA, and combinations thereof.

### Claim 16 (depends on 12)

The method of claim 12, wherein the at least one therapeutic agent comprises at least one gene sequence selected from the group consisting of vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMP), hepatocyte growth factor (HGF), and combinations thereof.

### Claim 17 (depends on 12)

The method of claim 12, wherein the at least one therapeutic agent comprises Cathepsin K (CTSK) siRNA, and wherein the at least one targeting agent comprises alendronate.

### Claim 18 (depends on 12)

The method of claim 12, wherein the at least one therapeutic agent comprises CTSK siRNA and at least one gene sequence selected from BMP and VEGF.

### Claim 19 (depends on 12)

The method of claim 12, wherein the gas is perfluorocarbon, and the polymer is albumin.

### Claim 20 (depends on 12)

The method of claim 12, wherein at least one of:
step (2) is performed at a temperature in a range of from about 0° C. to about 4° C.;
step (3) comprises a centrifugation step; and/or
step (4) is performed at a temperature in a range of from about 0° C. to about 4° C. for a period in a range of from about 24 hours to about 48 hours.

### Claim 21 (depends on 12)

The method of claim 12, wherein the nanobubble composition has a diameter in a range of from about 20 nm to about 200 nm.

### Claim 22 (depends on 12)

The method of claim 12, wherein at least one imaging agent is added to step (1) and/or (4) so that the at least one imaging agent is disposed in the hollow core and/or incorporated in the polymer shell.

### Claim 23

A method, comprising the step of:
(1) administering an effective amount of at least one ultrasound responsive targeted nanobubble composition to a patient in need thereof, wherein the nanobubble composition comprises a hollow core containing at least one gas, a polymer shell encircling the hollow core, at least one therapeutic agent disposed in the hollow core and/or encapsulated within the polymer shell, and at least one targeting agent incorporated in the polymer shell and/or attached to a surface of the polymer shell, wherein the at least one targeting agent targets the nanobubble composition to at least a portion of a musculoskeletal system of the patient.

### Claim 24 (depends on 23)

The method of claim 23, further comprising the steps of:
(2) allowing the nanobubble composition to travel through the patient so that the targeting agent binds to a target within at least a portion of the musculoskeletal system of the patient; and
(3) exposing the patient to ultrasound, wherein the ultrasound emits acoustic waves based on a determined frequency with an intensity and duration to rupture the nanobubble composition at the target within the patient.

### Claim 25 (depends on 23)

The method of claim 23, further comprising the step of exposing the patient to ultrasound prior to performing step (1).

### Claim 26 (depends on 23)

The method of claim 23, wherein the at least one targeting agent comprises an siRNA.

### Claim 27 (depends on 26)

The method of claim 26, wherein the siRNA is selected from the group consisting of a Cathepsin K (CTSK) siRNA, histone deacetylase 5 (HDAC5) siRNA, osteoprotegerin (OPG) siRNA, LDL receptor-related protein 5 (LRP5) siRNA, sclerostin siRNA, and combinations thereof.

### Claim 28 (depends on 23)

The method of claim 23, wherein the at least one therapeutic agent comprises at least one gene sequence selected from the group consisting of vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMP), hepatocyte growth factor (HGF), and combinations thereof.

### Claim 29 (depends on 23)

The method of claim 23, wherein the at least one therapeutic agent comprises Cathepsin K (CTSK) siRNA, and wherein the targeting agent comprises alendronate.

### Claim 30 (depends on 23)

The method of claim 23, wherein the gas is perfluorocarbon, and the polymer is albumin.

### Claim 31 (depends on 23)

The method of claim 23, wherein the nanobubble composition has a diameter in a range of from about 20 nm to about 200 nm.

### Claim 32 (depends on 23)

The method of claim 23, further comprising the steps of:
(2) allowing the nanobubble composition to travel through the patient so that the targeting agent binds to a target within at least a portion of the musculoskeletal system of the patient;
(3) exposing the patient to ultrasound, wherein the ultrasound emits acoustic waves based on a determined frequency with an intensity and duration to rupture the nanobubble composition at the target within the patient; and
(4) administering an effective amount of a second ultrasound responsive targeted nanobubble composition to a patient in need thereof, wherein the nanobubble composition comprises a hollow core containing at least one gas, at least one therapeutic agent disposed in the hollow core, a polymer shell encircling the hollow core, and at least one targeting agent incorporated in the polymer shell, wherein the at least one targeting agent targets the nanobubble composition to at least a portion of a musculoskeletal system of the patient.

### Claim 33 (depends on 32)

The method of claim 32, wherein in the nanobubble composition of step (1), the at least one therapeutic agent comprises Cathepsin K (CTSK) siRNA, and the targeting agent comprises alendronate, and wherein in the nanobubble composition of step (4), the at least one therapeutic agent comprises at least one gene sequence selected from BMP and VEGF.

### Claim 34 (depends on 23)

The method of claim 23, further defined as a method of treating a bone condition, disease, or disorder in the patient.

### Claim 35 (depends on 34)

The method of claim 34, wherein the bone condition, disease, or disorder comprises osteoporosis.

### Claim 36 (depends on 34)

The method of claim 34, wherein the bone condition, disease, or disorder is selected from the group consisting of a bone fracture, a bone defect, osteoarthritis, and a cancer.
